PD-1 inhibitor + oxaliplatin

This combination therapy regimen consists of a monoclonal antibody targeting the Programmed Cell Death Protein 1 (PD-1) receptor and the platinum-based cytotoxic agent oxaliplatin. Investigated in clinical trials led by Ruijin Hospital, this regimen is typically employed as an initial induction therapy for patients with HER2-negative advanced gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma. The PD-1 inhibitor component (which may include agents such as nivolumab, sintilimab, tislelizumab, or pembrolizumab) functions as an immune checkpoint inhibitor, blocking the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) to restore anti-tumor immune responses. Oxaliplatin is a small molecule cytotoxic agent that induces cell death by forming inter- and intra-strand DNA cross-links, which inhibit DNA synthesis and transcription. In the context of the Ruijin Hospital study, this combination is often administered as part of a chemotherapy backbone (e.g., CAPOX, SOX, or FOLFOX) prior to a maintenance phase involving targeted therapies like fruquintinib.

Other names

PD-1 + oxaliplatin-Ruijin Hospital-gastric adenocarcinoma-gastroesophageal junction adenocarcinomaPD-1 + oxaliplatinPD-1 monoclonal antibody + oxaliplatin-based chemotherapy